FGF2 and liver cancer: It has been shown that lymphangiogenesis is a critical initiator of tumor lymphatic metastasis.[10, 11] Accumulating evidence has demonstrated that upregulation of fibroblast growth factor 2 (FGF2), a lymphangiogenic growth factor, positively correlates with regional LN metastasis and poor survival in multiple human malignancies including liver cancer,[12] melanoma[13] and CSCC.[14] Previous research has indicated that inhibition of FGF2‐mediated signaling pathways using siRNA, anti‐FGF2 antibodies, or “FGF ligand trap” neutralizing antibodies can halt metastatic spread of human malignancies.